By Rob Curran Shares of PepGen rallied after the biotech company priced a follow-on offering of 7.5 million shares around Tuesday's closing price. The.
Wedbush restated their outperform rating on shares of PepGen (NASDAQ:PEPG – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $21.00 price target on the stock. PepGen Stock Performance NASDAQ:PEPG opened at $11.66 on Tuesday. The company has a market capitalization of $277.62 million, a price-to-earnings ratio […]
PepGen (NASDAQ:PEPG – Get Free Report) and Affimed (NASDAQ:AFMD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends. Insider and Institutional Ownership 71.8% of PepGen shares are […]
PepGen Inc. (PEPG) announced the FDA has lifted the full clinical hold and cleared the company's Investigational New Drug Application to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 in the U.